Here are the 10-K annual reports from AIM ImmunoTech Inc (AIMI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AIMI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMI filings page.
AIM ImmunoTech Inc. reports on an extensive R&D pipeline centered on its dsRNA drug Ampligen for late-stage pancreatic cancer, other solid tumors, antivirals, ME/CFS and post-COVID conditions, plus legacy product Alferon N Injection. The company highlights promising early- and mid-stage clinical data, orphan drug designations and multiple patents supporting oncology and antiviral strategies.
At the same time, AIM discloses recurring operating losses, net cash use, a working capital deficit and a stockholders’ deficit of approximately $9,783,000 as of December 31, 2025, leading management to conclude that substantial doubt exists about its ability to continue as a going concern. AIM is also not in compliance with NYSE American stockholders’ equity requirements and faces a potential delisting if it cannot raise equity above $6,000,000 by June 11, 2026, despite having regained compliance with minimum price rules via a 1‑for‑100 reverse split in 2025.
Mitigating steps include a third‑quarter 2025 vendor settlement that forgave $3,041,000 of legal fees in exchange for $1,875,000 of payments, recorded as other income, and a January 2026 stock dividend that reset Class E and F warrant terms, reduced their exercise price to $1.439 and allowed those warrants to be reclassified from liabilities to equity, which AIM states will significantly increase stockholders’ equity. The company also signed an agreement with Thermo Fisher Scientific’s PPD clinical research business to design an anticipated Phase 3 trial of Ampligen in late‑stage pancreatic cancer, reflecting its strategic focus on this indication as its most attractive commercial opportunity.